Compare ALIT & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALIT | GLUE |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | ALIT | GLUE |
|---|---|---|
| Price | $2.06 | $16.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $5.25 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 13.8M | 812.4K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 7.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | ★ $2,289,000,000.00 | $181,538,000.00 |
| Revenue This Year | N/A | $81.52 |
| Revenue Next Year | $1.56 | N/A |
| P/E Ratio | ★ N/A | $64.61 |
| Revenue Growth | N/A | ★ 1112.27 |
| 52 Week Low | $1.89 | $3.50 |
| 52 Week High | $7.66 | $18.15 |
| Indicator | ALIT | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 35.86 | 61.63 |
| Support Level | $2.00 | $15.21 |
| Resistance Level | $2.18 | $17.75 |
| Average True Range (ATR) | 0.11 | 0.87 |
| MACD | 0.02 | -0.13 |
| Stochastic Oscillator | 13.83 | 59.18 |
Alight Inc is a technology-enabled services company delivering human capital management solutions to many of complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth and leaves benefits) solutions, currently operates under one reportable segment, Employer Solutions. The Company completed the Divestiture of Alight's Professional Services segment and Alight's Payroll & HCM Outsourcing business within the Employer Solutions segment. The company operates in USA states and International market too.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.